CIP2A/p90 Autoantigen Rabbit pAb (一抗) | Bioss

bs-5948R

宠物抗体、农牧业/家禽抗体

CIP2A/p90 Autoantigen Rabbit pAb

蛋白磷酸酶PP2A癌抑制蛋白抗体

KIAA1524; NOCIVA; p90; C330027C09Rik; RGD1310335; CIP2A_HUMAN; CIP2A; Cancerous inhibitor of PP2A; p90 autoantigen; CIP2A_MOUSE; p90 autoantigen homolog; D3ZF50_RAT; cellular inhibitor of PP2A; cell proliferation regulating inhibitor of protein phosphatase 2A; cancerous inhibitor of protein phosphatase 2A

Rabbit

KLH conjugated synthetic peptide derived from human p90 Autoantigen: 601-700/905

IgG

Liquid

affinity purified by Protein A

Polyclonal

100 kDa

1mg/ml

0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.

This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Inhibition of protein phosphatase 2A (PP2A) activity has been identified as a prerequisite for the transformation of human cells. The protein, designated Cancerous Inhibitor of PP2A (CIP2A, p90 Autoantigen), interacts directly with the oncogenic transcription factor c-Myc, inhibits PP2A activity toward c-Myc serine 62 (S62), and thereby prevents c-Myc proteolytic degradation. In addition to its function in c-Myc stabilization, p90 Autoantigen promotes anchorage-independent cell growth and in vivo tumor formation. The oncogenic activity of p90 Autoantigen is demonstrated by transformation of human cells by overexpression of p90 Autoantigen. Importantly, p90 Autoantigen is overexpressed in two common human malignancies, head and neck squamous cell carcinoma (HNSCC) and colon cancer.